Amgen saw rising revenue in the fourth quarter of 2020, but the COVID-19 pandemic could dampen the outlook for the company and its investors in 2021, according to earnings released Feb. 2. The Thousand Oaks-based company, one of the world’s largest biotech firms and the biggest publicly traded company in the tri-county region, had $6.6…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
